D.E. Shaw & Co
IMRX icon

D.E. Shaw & Co’s Immuneering IMRX Stock Holding History

D.E. Shaw & Co’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
+203,663
New +$1.03M ﹤0.01% 3740
2022
Q2 		– Sell
-70,127
Closed -$454K – 5527
2022
Q1 		$454K Buy
+70,127
New +$674K ﹤0.01% 4428

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

D.E. Shaw & Co's IMRX Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Immuneering (IMRX) in Q2 2026: 203,663 shares worth $1.02M. The stake represents ﹤0.01% of the portfolio and ranks #3740 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in IMRX as recently as Q1 2022.

D.E. Shaw & Co first reported a position in IMRX in Q1 2022 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • D.E. Shaw & Co held 203,663 shares of Immuneering worth $1.02M as of Q2 2026.
  • Immuneering was a new D.E. Shaw & Co position in Q2 2026.
  • Immuneering made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3740 holding.
  • D.E. Shaw & Co first reported a position in Immuneering in Q1 2022 and has held it in 2 quarters since.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.